Likewise, PD-1 and PD-L1 blockade have produced exciting results in patients with a range of different solid cancers [41,42], and PD-1 blockade is now being investigated clinically in AML patients in combination with a dendritic cell-based cancer vaccine (NCT01096602). Here, PDCD1 is linked to cancer.